Loading viewer...
investor_presentation
Format: PDF investor_presentation
Commercial-stage biopharmaceutical company focused on developing novel cancer therapies through nuclear export inhibition. Presents pipeline progress for selinexor (XPOVIO) and eltanexor across multiple indications including multiple myeloma, endometrial cancer, and myelofibrosis, with cash runway into early 2024.
conference
80 Pages
investor_presentation
31 Pages
Vishnusurya Projects And Infra Limited
Reliq Health Technologies 2022 Investor Presentation
investor_presentationinvestor_presentation
15 Pages
Reliq Health Technologies Inc.
investor_presentation
Gaotu Techedu